An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Trial Profile

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2016

At a glance

  • Drugs Folitixorin (Primary) ; Pemetrexed
  • Indications Rectal cancer
  • Focus Adverse reactions
  • Acronyms LARS-2
  • Sponsors Isofol Medical
  • Most Recent Events

    • 04 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Sep 2013 Planned End Date changed from 1 Jul 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 04 May 2013 Planned number of patients changed from 52 to 70 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top